HOME >> MEDICINE >> NEWS
Twice daily imatinib could improve outcome for people with specific form of gastro-intestinal cancer

This release is also available in German.

Results of a randomised trial in this week's issue of THE LANCET suggest that a single daily 400 mg dose of imatinib--known to be a first-choice treatment for gastro-intestinal stromal tumours (GIST)--is sufficient to induce a therapeutic response; a doubling of a daily dose can slightly improve progression-free survival for patients.

Imatinib is approved worldwide for use in GIST, tumours which do not respond to conventional chemotherapy, which have a prevalence of around 20 per 100,000 population. Jaap Verweij (Erasmus University Medical Center, Netherlands) and colleagues from the European Organisation for Research and Treatment of Cancer (EORTC), the Italian Sarcoma Group (IRG), and the australasian Gastrointestinal Trials Group (AGITG) studied 946 patients with metastatic GIST who were randomly allocated either imatinib 400 mg once or twice a day.

50% of patients receiving two doses of imatinib a day, compared with 56% of patients given a single dose, were alive and free of disease progression at around 2 years follow-up. There was no difference in the proportion of patients (99%) who reported treatment side-effects; the optimum time for therapeutic effect after the start of treatment did not differ between the two groups (around 4 months).

Dr Verweij comments: "If the aim of treatment is response induction, a daily dose of 400 mg given for 46 months seems to be sufficient. However, in patients with widespread metastatic disease, the prolonged progression-free survival achieved with 400 mg twice daily might lead one to favour this regimen. Whether a similar outcome could be achieved with fewer side-effects by making use of the reduction in drug clearance over time--eg, with a starting dose of 400 mg daily followed by stepwise dose escalation to 400 mg twice a day--is still a matter for further clini
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
23-Sep-2004


Page: 1 2

Related medicine news :

1. Study: Among Heart Failure Patients, Women Survive Twice As Long As Men
2. Bullying among sixth graders a daily occurrence, UCLA study finds
3. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
4. African children with HIV would benefit from daily doses of cheap antibiotic
5. Weekend use matches daily drops for lazy eye
6. New ways identified to treat lazy eye in children: Beyond eye patches and daily drops
7. Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment
8. Study finds once-daily Valcyte prevents serious viral infection after kidney transplant
9. Max daily OTC dose of acetaminophen shows efficacy comparable to Rx doses of naproxen for OA pain
10. New study finds even a small amount of psoriasis can negatively impact daily life
11. OHSU study shows four daily servings of fruits & vegetables reduce breast cancer risk by half

Post Your Comments:
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
(Date:4/17/2014)... these days to find a colored ribbon representing a disease. ... But what color ribbon does one think of with lung ... for many suffering from the disease, black may be the ... consisting of lung cancer patients, primarily smokers between the ages ... on the stigma often felt by these patients, the emotional ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
(Date:1/14/2014)... Pa. , Jan. 14, 2014 Dynamic Healthcare Services, ... announced today that it acquired Progressive Home Medical Equipment, Inc. ... 7, 2014. The terms of the acquisition were not disclosed. ... equipment ("DME") company providing a wide range of sleep, mobility, ...
(Date:1/14/2014)... , a manufacturer of ergonomically designed laboratory equipment for ... Japan to sell and service the Hitachi ... will utilize its network of sales professionals throughout the ... offer assistance in application use, product benefits and features, options and ...
(Date:1/14/2014)... PORT WASHINGTON, New York , January 14, ... the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, ... sales growth for the fourth straight year.   ... of exposure for pharmacy technicians, pharmacists, nurses and ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Equashield's Sales Grow by 60% in 2013 2
Cached News: